Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Immunocellular Therapeutics, Ltd. (IMUC)
:IMUC
Holding IMUC?
Track your performance easily
IMUC Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.07 - $0.40
Previous CloseN/A
Volume63.00
Average Volume (3M)2.54K
Market Cap
$18.11M
Enterprise ValueN/A
Total Cash (Recent Filing)$27.65M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.19
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding113,270,750
10 Day Avg. Volume1,459
30 Day Avg. Volume2,538
Standard Deviation0.32
R-Squared0.00538
Alpha0.03
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
IMUC FAQ
What was Immunocellular Therapeutics, Ltd.’s price range in the past 12 months?
Immunocellular Therapeutics, Ltd. lowest stock price was $0.07 and its highest was $0.40 in the past 12 months.
What is Immunocellular Therapeutics, Ltd.’s market cap?
Immunocellular Therapeutics, Ltd.’s market cap is $18.11M.
When is Immunocellular Therapeutics, Ltd.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Immunocellular Therapeutics, Ltd.’s earnings last quarter?
Immunocellular Therapeutics, Ltd. released its earnings results on Aug 13, 2018. The company reported -$0.1 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.1.
Is Immunocellular Therapeutics, Ltd. overvalued?
According to Wall Street analysts Immunocellular Therapeutics, Ltd.’s price is currently Overvalued.
Does Immunocellular Therapeutics, Ltd. pay dividends?
Immunocellular Therapeutics, Ltd. does not currently pay dividends.
What is Immunocellular Therapeutics, Ltd.’s EPS estimate?
Immunocellular Therapeutics, Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Immunocellular Therapeutics, Ltd. have?
Immunocellular Therapeutics, Ltd. has 113,270,750 shares outstanding.
What happened to Immunocellular Therapeutics, Ltd.’s price movement after its last earnings report?
Immunocellular Therapeutics, Ltd. reported an EPS of -$0.1 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Immunocellular Therapeutics, Ltd.?
Currently, no hedge funds are holding shares in IMUC
---
Company Description
Immunocellular Therapeutics, Ltd.
ImmunoCellular Therapeutics, Ltd. is a clinical-stage company, which engages in the development of immune-based therapies for the treatment of cancers. The company's lead product candidate, ICT-107, is a dendritic cell-based immunotherapy targeting multiple tumor-associated antigens on glioblastoma stem cells. Its pipeline also includes ICT-121, a patient-specific, dendritic cell-based immunotherapy targeting the CD133 antigen on stem cells in recurrent glioblastoma; ICT-140, a patient-specific, dendritic cell-based immunotherapy targeting antigens on ovarian cancer stem cells; and the Stem-to-T-cell research program which engineers the patient's hematopoietic stem cells to generate antigen-specific cancer-killing T cells. The company was founded on January 30, 2006 and is headquartered in Calabasas, CA.
---
Technical Analysis
Northwest Biotherapeutics
―
Advaxis
―
Brainstorm Cell Therapeutics
―
Cyclacel Pharmaceuticals
―
Kura Oncology
―
Bio-Path Holdings
―
---